Resources

Trever Bivona, M.D. Ph.D. is a cell and molecular biologist and a laboratory-based physician scientist at the University of California, San Francisco where he is a medical oncologist and Professor of Medicine and of Cellular and Molecular Pharmacology. He is a cancer biologist who leads a research program focused on signal transduction and cancer genetics and the molecular basis of tumor initiation, evolution, and drug resistance. A major area of interest is the function and therapeutic targeting of oncogenic receptor tyrosine kinases (RTKs) such as EGFR and ALK as well as RAS GTPase signaling. A recent discovery and area of interest is the role of membraneless cytoplasmic biomolecular condensates formed by certain oncogenic RTKs in driving oncogenic signaling through RAS and other proteins to promote cancer. The overall goal of this research program is to understand the regulatory principles underlying cancer cell signaling and tumor evolution to improve cancer therapy and patient survival and quality of life. Dr. Bivona received a NIH Director’s New Innovator Award and is an elected member of the American Society for Clinical Investigation. Dr. Bivona is currently Principal Investigator of the NIH/NCI U54 Bay Area Drug Resistance and Sensitivity Center and is a Chan-Zuckerberg Biohub Senior Investigator.

Dr. Conolly is a Full Professor of Bioengineering and Electrical Engineering and Computer Sciences at UC Berkeley, where he holds the Montford G. Cook Endowed Chair. He was elected Chair of the UC Berkeley-UCSF Joint Graduate Group in Bioengineering from 2006-2009. He currently serves as Vice Chair of Instruction in BioE at UC Berkeley.
Dr. Conolly specializes in medical imaging and biosensing hardware, with a focus on Magnetic Particle Imaging and Magnetic Resonance Imaging. His research group has built all of the Magnetic Particle Imaging scanners now in the USA. MPI shows extraordinary promise as a safe, noninvasive, and quantitative imaging method. MPI biomedical applications include stem cell tracking, perfusion imaging, angiography and cancer imaging. Prof. Conolly has won research support from CIRM, NIH and UC Discovery, the Siebel Foundation and the Keck Foundation.

He received his B.S in Electrical Engineering from Boston University, and his M.S. and Ph.D. in Electrical Engineering from Stanford University. Dr. Conolly has 30 patents in various stages of approval, and more than half of these have been licensed by industry. In 2004, Prof. Conolly was a recipient of the prestigious Stanford’s Outstanding Inventor award.

Jason Cyster is a Professor in the Department of Microbiology and Immunology at the University of California, San Francisco. Cyster is an immunologist recognized for his work on the cues guiding immune cell movements in lymphoid organs and for defining the mechanism of lymphocyte egress from tissues. He is also known for his use of real-time 2-photon microscopy to study immune cell migration and interaction dynamics within tissues during antibody responses. Cyster was born in Western Australia and grew up on a cattle farm in the south of the state. He graduated from the University of Western Australia with a degree in Biochemistry and Microbiology and from the University of Oxford with a D.Phil. in Immunology in 1992. He was a postdoctoral fellow in immunology at Stanford University School of Medicine and he joined the faculty at the University of California, San Francisco in 1995.

Joe DeRisi is an interdisciplinary scientist whose work combines genomics, bioinformatics, biochemistry, and bioengineering to study autoimmune, parasitic, and viral diseases in a wide range of organisms.

One of the early pioneers of DNA microarray technology and whole-genome expression profiling, he was chosen for a MacArthur Fellowship in 2004 for his work with microarrays, particularly as a member of a team that identified and characterized the virus (now known as SARS-CoV-1) that caused the original SARS outbreak in 2003.

DeRisi has been a leading advocate of unbiased methods for pathogen discovery, disease tracking, and clinical diagnosis using metagenomic sequencing. Over the past two decades his work has increased the power, versatility, and clinical utility of metagenomic tools, laying the groundwork for the CZ ID platform now used for pathogen surveillance and diagnostics in low- and middle-income countries around the world. More recently, together with colleagues at UC San Francisco (UCSF), he has increasingly focused on the use of programmable phage display technologies for investigating previously unknown autoimmune diseases.

DeRisi graduated from UC Santa Cruz with a B.A. in Biochemistry and Molecular Biology, before earning his Ph.D. in Biochemistry with Patrick O. Brown at Stanford University. A member of the American Academy of Arts and Sciences, the National Academy of Sciences, and the National Academy of Medicine, DeRisi is a Professor in the Department of Biochemistry and Biophysics at UCSF. He was previously a Searle Scholar, a Packard Fellow, and an Investigator of the Howard Hughes Medical Institute before launching the CZ Biohub in San Francisco in 2016 along with Steve Quake.

Early in the COVID-19 pandemic, DeRisi and his team at the Biohub and at UCSF worked together to rapidly launch a clinically certified testing facility, which ultimately offered free clinical tests and SARS-CoV-2 genome sequencing to all 58 California Departments of Public Health, as chronicled in Michael Lewis’s 2021 book, The Premonition: A Pandemic Story.

Dr. John Dueber is the Associate Professor of Bioengineering at University of California, Berkeley. He earned his Ph.D. in Bioengineering from University of California, San Francisco, under the advisory of Wendell Lim. He is currently the Principal Investigator of the Dueber Lab at UC Berkeley. The Dueber Lab develops strategies for introducing designable, modular control over living cells. The Dueber Lab is particularly interested in generating technologies for improving engineered metabolic pathway efficiency and directing flux. The projects have applications in development of biofuels, specialty chemicals, and environmentally friendly processes.

Pamela England, PhD is Professor of Pharmaceutical Chemistry at the UCSF School of Medicine. England’s research focuses on the development and use of small molecules to manipulate and monitor the activities of biologically important ligand-receptor systems. Execution of these research projects typically involves a combination of synthetic chemistry, computational chemistry, structural biology, and appropriate biochemical and biological assays.

England completed her PhD in Chemistry at Massachusetts Institute of Technology (MIT) in 1995 and her Bachelor of Science in Chemistry at the University of California, Los Angeles in 1989.

England received UCSF Dean’s Award for Excellence in Teaching in 2018, 2019, and 2021, and also received the UCSF CTSI Catalyst Award in 2020 and UCSF Roger’s Family Foundation Bridging the GAP Award in 2015.

Dr. Dan Fletcher is the department chair in the bioengineering department and biological systems program at the University of California, Berkeley, where his research focuses on the biophysics of cell movements and the cytoskeleton and development of biomedical devices. Recent work from his laboratory includes direct measurement of the actin networks that drive crawling motility, development of vesicle encapsulation technology for cellular reconstitution, and demonstration of fluorescence microscopy on a mobile phone.

Fletcher received a B.S.E. from Princeton University and a D.Phil. from Oxford University, where he was a Rhodes Scholar. He received a Ph.D. in mechanical engineering from Stanford University as an NSF graduate research fellow and was a postdoctoral fellow in biochemistry at the Stanford University School of Medicine as part of the Stanford Bio-X program. His research has received an NSF CAREER Award, a National Inventors Hall of Fame Collegiate Award, and was designated “Best of What’s New” by Popular Science magazine.

Last year Fletcher was named a White House Fellow and worked with the Office of Science and Technology Policy at the White House. He is also deputy director of the physical biosciences division of Lawrence Berkeley National Laboratory (LBNL), faculty affiliate of the QB3 and CITRIS Institutes at UC Berkeley, a member of the bioengineering, biophysics, and nanoscale science and engineering graduate groups, and deputy director of the Cell Propulsion Lab, an NIH Nanomedicine Development Center based at UCSF.

Matt Francis is the Department of Chemistry Chair and the T.Z. and Irmgard Chu Distinguished Professor in Chemistry at UC Berkeley. Matt was born in Ohio and received his undergraduate degree in Chemistry from Miami University in Oxford, OH in 1994. From 1994-1999 he attended graduate school at Harvard University, working in the lab of Prof. Eric Jacobsen. His Ph.D. research involved the development of combinatorial strategies for the discovery and optimization of new transition metal catalysts. He then moved to UC Berkeley, where he was a Postdoctoral Fellow in the Miller Institute for Basic Research in Science. He worked under the guidance of Prof. Jean Fréchet, focusing on the development of DNA-based methods for the assembly of polymeric materials and the application of dendrimers for drug delivery. Matt started his independent career in the UC Berkeley Chemistry Department in 2001, and has built a research program involving the development of new organic reactions for protein modification. These new chemical tools have then been used to modify biomolecular assemblies to prepare new materials for diagnostic imaging, wastewater treatment, and solar cell development. For his research accomplishments, Matt has received the Dreyfus Foundation New Faculty Award, an NSF Career Award, a GlaxoSmithKline Young Investigator Award, the 2017 Bioconjugate Chemistry Lectureship Award from the American Chemical Society, and the 2019 Arthur C. Cope Scholar Award from the American Chemical Society. Matt became the chair of the chemistry department at UC Berkeley in 2018. Matt has also received the UC Berkeley Departmental Teaching Award on three occasions, the Noyce Prize for Excellence in Undergraduate Teaching, and the 2009 University Distinguished Teaching Award.

As a scientist with training in genetics and cellular biology, 10+ years experience in the biotech industry as well as over 20 years experience in executive search, Mimi has helped build and advise multiple organizations ranging from venture-backed start-ups to multi-national biopharmaceutical companies. Initially focused in oncology, Mimi joined Triton Biosciences where she conducted early research targeting HER-2 positive breast cancers with a combination of monoclonal antibodies and chemotherapy drugs. Upon the sale of the company, Mimi joined Hana Biologics as Director of Cell Biology and helped transition it into gene therapy through the acquisition of Somatix Therapy Corporation. In 1992, she co-founded Avigen, which was the first to use AAV vectors for gene delivery. Mimi entered the executive search field in 1994 to focus on top leadership in global Biotechnology and R&D organizations and helped numerous organizations with Boards of Directors, VP and C-level roles.

She currently serves as an Honorary Member of the CEO Roundtable on Cancer.

Mimi graduated with a BA with Honors in Biological Sciences from the University of Chicago, PhD in Genetics from the University of California, Berkeley, and Post-doctoral Fellow at Stanford University where she was the recipient of a Damon Runyon Cancer Fund Fellowship Award.